EN DE

Dr QUIVRIN Magali

Fiche personne

coordonnées

Centre Georges François Leclerc
1 rue du Professeur Marion
21079 DIJON

03 80 73 75 18

mquivrin@cgfl.fr

Territoire

Bourgogne

Statut

Hospitalier

affiliation

Centre Georges-François Leclerc (CGFL)

équipes/plateformes

Equipe Département de Radiothérapie

Recherche

Expertises :
- Clinique:Radiothérapie

Projets

Étude de Phase II multicentrique évaluant l’efficacité et tolérance d’une radiothérapie hypo-fractionnée pelvi-prostatique suivie d’un boost (radiothérapie externe ou curiethérapie à haut débit de dose) chez des patients porteurs d’un adénocarcinome prost (HYPO Prostate)

2016 - Porteur du projet : Dr QUIVRIN Magali

Publications

A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532).

Tombal BF, Gomez-Veiga F, Gomez-Ferrer A, López-Campos F, Ost P, Roumeguere TA, Herrera-Imbroda B, D'Hondt LA, Quivrin M, Gontero P, Villà S, Khaled H, Fournier B, Musoro J, Krzystyniak J, Pretzenbacher Y, Loriot Y

Eur Urol Oncol. 2024 01 24;:

Cardiac stereotactic radiation therapy for refractory ventricular arrhythmias in patients with left ventricular assist devices.

Benali K, Lloyd MS, Petrosyan A, Rigal L, Quivrin M, Bessieres I, Vlachos K, Hammache N, Bellec J, Simon A, Laurent G, Higgins K, Garnier F, de Crevoisier R, Martins R, Da Costa A, Guenancia C

J Cardiovasc Electrophysiol. 2023 11 29;:

A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.

Roussot N, Fumet JD, Limagne E, Thibaudin M, Hervieu A, Hennequin A, Zanetta S, Dalens L, Fourrier T, Galland L, Jacob P, Bertaut A, Rederstorff E, Chevalier C, Ghirardi S, Gilbert E, Khoukaz A, Martin E, Nicolet C, Quivrin M, Thibouw D, Vulquin N, Truc G, Rouffiac M, Ghiringhelli F, Mirjolet C

BMC Cancer. 2023 11 9;23(1):1080

Cardiac Stereotactic Radiation Therapy for Refractory Ventricular Arrhythmias in Patients With Left Ventricular Assist Device.

Benali K, Higgins K, Quivrin M, Bessieres I, Wight JA, Gupta D, Martins R, Shah AD, Guenancia C, Lloyd MS

JACC Clin Electrophysiol. 2023 05;9(5):707-709

Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol.

Rogé M, Pointreau Y, Sargos P, Meyer E, Schick U, Hasbini A, Rio E, Bera G, Ruffier A, Quivrin M, Chasseray M, Latorzeff I, Martin E, Guimas V, Pommier P, Leroy T, Ronchin P, Lepinoy A, Grand A, Cartier L, Didas O, Denis F, Libois V, Blanc-Lapierre A, Supiot S

Clin Transl Radiat Oncol. 2023 05;40:100613

Predictive value of health-related quality of life on radiotherapy-related toxicities in patients with head and neck cancer.

Billa O, Bonnetain F, Chamois J, Ligey A, Ganansia V, Renard S, Maillard S, Quivrin M, Vulquin N, Truntzer P, Noel G, Maingon P, Dabakuyo-Yonli TS

Support Care Cancer. 2023 04 14;31(5):268

Elevated Baseline Neutrophil Count Correlates with Worse Outcomes in Patients with Muscle-Invasive Bladder Cancer Treated with Chemoradiation.

Meunier S, Frontczak A, Balssa L, Blanc J, Benhmida S, Pernot M, Quivrin M, Martin E, Hammoud Y, Créhange G, Boustani J

Cancers (Basel). 2023 03 21;15(6):

The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence After Previous External Radiation Therapy: Phase 1 Results from the GETUG-AFU 31 Study.

Pasquier D, Lacornerie T, Supiot S, Pommier P, Quivrin M, Simon JM, Loos G, Meyer E, Calais G, Peiffert D, Vandendorpe B, Aymes E, Leguillette C, Brihoum M, Nenan S, Cormier L, Le Deley MC, Lartigau EF

Eur Urol Oncol. 2023 02 6;:

Outcomes following brachytherapy boost for intermediate- and high-risk prostate cancer: a retrospective bicenter study by the SFRO Brachytherapy Group.

Ka K, Schiappa R, Terlizzi M, Mallet F, Martin E, Chand ME, Demogeot N, Peiffert D, Pommier P, Quivrin M, Kissel M, Pasquier C, Khalifa J, Hannoun-Levi JM, Blanchard P

Radiother Oncol. 2023 01 10;:109460

Clinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and Asia.

Slotman BJ, Clark MA, Özyar E, Kim M, Itami J, Tallet A, Debus J, Pfeffer R, Gentile P, Hama Y, Andratschke N, Riou O, Camilleri P, Belka C, Quivrin M, Kim B, Pedersen A, van Overeem Felter M, Kim YI, Kim JH, Fuss M, Valentini V

Radiat Oncol. 2022 08 22;17(1):146

Salvage Involved-Field and Extended-Field Radiation Therapy in Positron Emission Tomography-Positive Nodal Recurrent Prostate Cancer: Outcomes and Patterns of Failure.

Pêtre A, Quivrin M, Briot N, Boustani J, Martin E, Bessieres I, Cochet A, Créhange G

Adv Radiat Oncol. 2022 07 28;8(1):101040

Randomized Trial Assessing the Impact of Routine Assessment of Health-Related Quality of Life in Patients with Head and Neck Cancer.

Billa O, Bonnetain F, Chamois J, Ligey A, Ganansia V, Noel G, Renard S, Maillard S, Quivrin M, Vulquin N, Truntzer P, Dabakuyo-Yonli TS, Maingon P

Cancers (Basel). 2021 Jul 29;13(15):

Patterns of Bone Failure in Localized Prostate Cancer Previously Irradiated: The Preventive Role of External Radiotherapy on Pelvic Bone Metastases.

Grapin M, Quivrin M, Bertaut A, Martin E, Cormier L, Ladoire S, Cochet A, Créhange G

Front Oncol. 2019 ;9:70

Salvage extended field or involved field nodal irradiation in F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer.

Lépinoy A, Silva YE, Martin E, Bertaut A, Quivrin M, Aubignac L, Cochet A, Créhange G

Eur. J. Nucl. Med. Mol. Imaging. 2018 Sep 28;:

Inferring postimplant dose distribution of salvage permanent prostate implant (PPI) after primary PPI on CT images.

Girum KB, Lalande A, Quivrin M, Bessières I, Pierrat N, Martin E, Cormier L, Petitfils A, Cosset JM, Créhange G

Brachytherapy. 2018 Sep 11;:

Salvage brachytherapy as a modern reirradiation technique for local cancer failure: The Phoenix is reborn from its ashes.

Quivrin M, Peignaux-Casasnovas K, Martin É, Rouffiac M, Thibouw D, Chevalier C, Vulquin N, Aubignac L, Truc G, Créhange G

Cancer Radiother. 2018 May 30;:

Impact of rectal distension on prostate CBCT-based positioning assessed with 6 degrees-of-freedom couch.

Charret J, Salleron J, Quivrin M, Mazoyer F, Lesueur P, Martin E, Peiffert D, Créhange G

Pract Radiat Oncol. 2018 Mar 9;:

Impact of waiting time on nodal staging in head and neck squamous-cell carcinoma treated with radical intensity modulated radiotherapy.

Chevalier C, Bertaut A, Quivrin M, Vulquin N, Desandes C, Folia M, Duvillard C, Truc G, Crehange G, Maingon P

Clin Transl Radiat Oncol. 2016 Dec;1:27-32

Multiparametric MRI and post implant CT-based dosimetry after prostate brachytherapy with iodine seeds: The higher the dose to the dominant index lesion, the lower the PSA bounce.

Quivrin M, Loffroy R, Cormier L, Mazoyer F, Bertaut A, Chambade D, Martin E, Maingon P, Walker P, Crehange G

Radiother Oncol. 2015 Aug 28. pii: S0167-8140(15)00445-4

Mapping of failures after radiochemotherapy in patients with non-metastatic esophageal cancer: A posteriori analysis of the dose distribution in the sites of loco-regional relapse.

Bednarek C, Crehange G, Quivrin M, Cueff A, Vulquin N, Chevalier C, Cerda T, Petegnief Y, Mazoyer F, Maingon P, Bosset JF, Servagi Vernat S

Radiother Oncol. 2015 Jul 27. pii: S0167-8140(15)00371-0

[Radiochemotherapy for esophageal cancer: which nodes should be irradiated?].

Crehange G, Quivrin M, Vulquin N, Serre AA, Maingon P

Cancer Radiother. 2014 Oct;18(5-6):577-82

Stereotactic Body radiation therapy for liver tumors with or without rotational intensity modulated radiation therapy.

Nouhaud E, Crehange G, Cueff A, Quivrin M, Rouffiac-Thouant M, Mineur L, Garcia R, Chamois J, Maingon P

BMC Res Notes. 2013 Nov 27;6:492